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Background: Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) is a negative
immune regulator on the surface of T cells. In humans, heterozygous germline mutations
in CTLA4 can cause an immune dysregulation syndrome. The phenotype comprises a
broad spectrum of autoinflammatory, autoimmune, and immunodeficient features. An
increased frequency of malignancies in primary immunodeficiencies is known, but their
incidence in CTLA-4 insufficiency is unknown.
Methods: Clinical manifestations and details of the clinical history were assessed in a
worldwide cohort of 184CTLA4mutation carriers. Whenever a malignancy was reported,
a malignancy-specific questionnaire was filled.
Results: Among the 184 CTLA4 mutation carriers, 131 were considered affected,
indicating a penetrance of 71.2%. We documented 17 malignancies, which amounts
to a cancer prevalence of 12.9% in affected CTLA4 mutation carriers. There were ten
lymphomas, five gastric cancers, one multiple myeloma, and one metastatic melanoma.
Seven lymphomas and three gastric cancers were EBV-associated.
Conclusion: Our findings demonstrate an elevated cancer risk for patients with CTLA-4
insufficiency. As more than half of the cancers were EBV-associated, the failure to
Egg et al. Malignancies in CTLA-4 Insufficiency
control oncogenic viruses seems to be part of the CTLA-4-insufficient phenotype. Hence,
lymphoproliferation and EBV viral load in blood should be carefully monitored, especially
when immunosuppressing affected CTLA4 mutation carriers.
Keywords: CTLA4, combined immunodeficiency, primary immunodeficiency, malignancy, cancer predisposition,
EBV, CMV
INTRODUCTION
Antibody-mediated autoimmunity, recurrent infections,
lymphoproliferation, and lymphoid infiltrations into the lung,
the bowel, or the central nervous system, characterize the clinical
spectrum of CTLA-4-insufficient patients (1, 2). Furthermore,
recent publications reported on malignancies in those patients
(3–6).
Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) is
an essential negative regulator of T cell-mediated immune
responses (7). CTLA-4 competes with CD28 with higher affinity
for the binding to CD80 and CD86 (also known as B7-1 and
B7-2), two costimulatory molecules on the surface of dendritic
cells, activated B cells, and monocytes. CD28 is constitutively
expressed on T cells whereas CTLA-4 is mostly stored in vesicles
and becomes upregulated in conventional T cells upon activation.
Whereas CD28 delivers a positive signal into T cells leading
to T cell activation and effector cell differentiation, the ligation
of CTLA-4 to CD80 and CD86 delivers a negative signal to
T cells, limiting IL-2 production, proliferation, and survival
of T cells (8). Thus, heterozygous CTLA4 germline mutations
impair the suppressive function of T cells and cause an immune
dysregulation syndrome characterized by an activated immune
system with autoimmune features and organ pathology caused
by infiltrating effector T cells (2).
Given that patients with heterozygous CTLA4 mutations
have an activated immune system consisting of an expansion
of effector T cells and given that anti-CTLA-4 treatment is
successfully used in the treatment of certain cancers, one would
expect that patients with CTLA-4 insufficiency have a lower
risk to develop cancer (2, 6, 9). Hence, our study aimed to
assess whether a heterozygous germline mutation in CTLA4 is
associated with a decreased risk to develop cancer.
Abbreviations: ABVD, Adriamycin (Doxorubicin), Bleomycin, Vinblastine,
Dacarbazine; allo-HSCT, Allogeneic hematopoietic stem cell transplantation;
BMT, Bone marrow transplantation; CIN, Cervical intraepithelial neoplasia;
CVID, Common variable immunodeficiency; DA-R-EPOCH, Rituximab,
Etoposide, Prednisolone, Oncovin, Cyclophosphamide, Hydroxychloroquine;
HSCT, Hematopoietic stem cell transplantation; IGRT, Immunoglobulin
replacement therapy; ITP, Immune thrombocytopenia; MS, Multiple Sclerosis;
LRBA, Lipopolysaccharide-responsive and beige-like anchor protein; PBSC,
Peripheral blood stem cells; PCR, Polymerase chain reaction; PET-CT,
Positron-emission tomography and computer tomography; PID, Primary
immunodeficiency; PD-1, Programmed cell death protein; R-BEAM,
Rituximab, Camustin, Ara C, Etoposid, Melphalan; R-CHOP, Rituximab,
Cyclophosphamide, Hydroxychloroquine (Doxorubicin), Vincristine (Oncovin),
Prednisolone; R-CVAD, Rituximab, Cyclophosphamide, Vincristine, Adriamycin,
Dexamethasone; R-DHAP, Rituximab, Dexamethasone, high Ara-C (Cytarabine),
Cisplatin; R-ICE, Rituximab, Ifosfamide, carboplatin, etoposide; VIN, Vulvar
intraepithelial neoplasia.
MATERIALS AND METHODS
We have collected a world-wide cohort of 184 CTLA4 mutation
carriers. Of these, 131 were considered affected (mutation
carriers were classified as affected if they showed clinically
apparent symptoms related to CTLA-4 insufficiency requiring
medical care or treatment), indicating a reduced penetrance of
the disease of 71.2%. A malignancy-specific questionnaire was
provided to collaborating physicians, who had reported any
malignancy in their CTLA-4-insufficient patients, to collect data
on cancer entity, cancer induction, and treatment outcome. This
study was carried out in accordance with the recommendations
for studies with human subjects of the scientific committee
at the University Medical Center of Freiburg. All physicians
confirmed that their patients had signed an informed consent
under local ethics-approved protocols and in accordance with
the Declaration of Helsinki. The protocol was approved by the
scientific committee at the University Medical Center of Freiburg
(Approval No. 251/13_KW and 295/13_140782).
The following patients are part of a single-center retrospective
analysis of malignancy cases associated with common
variable immunodeficiency (CVID) as well: A.III.1 = ID
21, MM.II.1= ID 7, and JJ.II.1= ID 13.
All statistics and figures were computed and created by using
R (version 3.4.1). Person-time of risk described the time period
from date of birth to last follow-up or until an event (cancer
or death) occurred and was used to compute life-time incidence
rate. Individuals were censored, if follow-up date was missing
(six individuals). Incidence rates of malignancies in CTLA4
wildtype population are in cases per 100,000 persons per year
and are age-adjusted to the 2000 US Std Population (19 age
groups—Census P25-1130 for US rates), respectively to the SEGI-
world standardization for German rates and were arithmetically
averaged (10, 11).
RESULTS
We identified 17 patients with a malignancy (Table 1). This
amounts to a cancer prevalence of 12.9% in patients with CTLA-
4 insufficiency in our cohort. Among the 17 cases there were
two entities predominant: ten patients with lymphomas and
five patients with gastric cancers. Interestingly, seven of ten
lymphomas and three of five gastric cancers were EBV-associated.
Additionally, one case of multiple myeloma, and one case of
metastatic melanoma were reported.
The cumulative person-years of documentation in our cohort
of 184 CTLA4 mutation carriers comprise 3,825 patient-years
in total. Taken together, the reported 17 cases result in 4.4 new
malignancies per 1,000 patients per year.
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The median age of onset was 32 years for lymphoma and 34
years for gastric cancer. The Hodgkin lymphomas occurred at a
median age of 29 years and the Non-Hodgkin-Lymphomas at a
median age of 48 years. Themultiplemyeloma occurred at the age
of 75 years and the melanoma at the age of 24 years. The median
age of death was 53 years for DLBCL, 35 years for gastric cancer,
and 43 years in total.
Six of the 10 lymphomas were classified as Hodgkin
lymphomas, of whom one patient is currently on treatment
(A.III.1), four patients reached a complete remission (B.II.3,
L.II.2, JJ.II.1, MM.II.1), and one patient died (H.II.1). Two out of
four patients who were cured received chemotherapy (A(B)VD
protocol) followed by a successful allo-HSCT (B.II.3 and L.II.2).
Four of ten lymphomas were classified as Non-Hodgkin
lymphomas (NHL): Three diffuse large B cell lymphomas
(DLBCL) in K.II.1, UU.III.3, and CO.I.1, and one Burkitt
lymphoma in FF.II.1. All four patients died due to their NHL.
Additionally, one patient (CM.I.2) developed a multiple
myeloma and is currently on treatment. All details in Table 1.
The five patients with gastric cancer had a long history of
autoimmune enteropathy or atrophic gastritis. Three of the
gastric carcinomas were EBV-associated, two were positive for
CMV and Helicobacter pylori (Table 1). Three of the patients
have previously been published (G.III.2, M.III.3 and B.II.4)
(2, 4, 5). For treatment, three out of five patients underwent
total gastrectomy, one received subtotal gastrectomy, and one
patient (XX.II.1) underwent endoscopic resection and stopped
his recent abatacept therapy. The first gastroscopy after 6
months in patient XX.II.1 showed quiescent conditions and
gastrectomy might finally be performed when aggravation
occurs. So far, remission was reached in four patients, however,
patient M.II.3 never fully recovered and died 25 months after
gastrectomy.
The two further malignancies comprise one patient (CZ.II.2),
who had developed a metastatic melanoma and precancerous
cervical and vulvar lesions, indicating decreased control of
Human papilloma viruses (HPV). Excision of the melanoma
was performed, but suspicious PET-CT avidity prompted further
interventions of which results are currently pending. The second
patient (CM.I.2) had developed an axillary sarcoma at the age
of 60 years, had reached clinical remission, but had presented
recently an amyloidosis-associated multiple myeloma at the age
of 75 years and is currently on treatment.
Histologically, the hyperinflammatory condition of CTLA-4-
insuffient patients often manifests at mucosal surfaces of the
gastrointestinal tract but may also damage associated organs
as the liver (Figure 1). On the other hand, the disturbed
immunosurveillance allows neoplastic lymphoproliferations and
solid cancers to develop, often promoted by viruses as EBV and
CMV (Figures 2–4).
CASE REPORTS
Lymphomas
Patient A.III.1 is a 30-year-old female, who presented with
antibody deficiency at age 15 and the diagnosis of CTLA-4
insufficiency was made at the age of 27 years. Additional
complicating features included CNS involvement, psoriatic skin
irritation, arthralgia, and a recurrent enteropathy, treated by
steroids and immunoglobulin replacement therapy (IGRT).
By the age of 30 years she had lost 6 kg of weight during 3
months and multiple enlarged lymph nodes on both sides of the
diaphragm were detected. Supraclavicular lymph node resection
revealed a grade IV EBV-associated Hodgkin lymphoma with
mixed cellularity (Figure 2). Laboratory findings showed a viral
EBV load of 59,000 IU/ml blood.
The EBV viremia was treated with four courses of rituximab.
The patient recently received her first course of AVD-
Brentuximab and is currently stable.
Patient H.II.1 was a 21-year-old male, who presented with
protracted diarrhea, ITP, and AIHA at the age of 10 years. The
cytopenias became steroid-dependent and prompted intensive
immunosuppression and finally splenectomy at the age of 20
years.
Moreover, he developed lymphocytic CNS lesions
and recurrent generalized lymphadenopathies during his
adolescence. Repeated biopsies revealed polyclonal cellularity
in the lymph nodes and aplasia, fibrosis, and nodular
lymphocytic aggregates in the bone marrow, compatible
with an autoimmune lymphoproliferative syndrome-phenotype
(Figure 1). Additional, he suffered from a cholestatic giant cell
hepatitis at the age of 17 years (Figure 1).
At the age of 21 years, his EBV load had risen from 2,000
copies/ml to 8,400 copies/ml within 4 weeks, accompanied with
high fevers and worsening clinical condition. He was admitted to
intensive care due to progressive respiratory insufficiency, severe
pancytopenia, and severe colitis. Despite immunosuppressive
treatment with everolimus and prednisolone, rituximab, and
high dose dexamethasone, the patient deteriorated and developed
sepsis. Sequential therapy approaches with MMF, ATG, and
G-CSF were made and quadruple-therapy for a concomitant
atypical tuberculosis was initiated. Nonetheless, his condition
worsened and he died 4 months after the onset of his EBV
viremia. Pathology revealed post-mortem the diagnosis of an
EBV-associated classic Hodgkin lymphoma with bone marrow
infiltration (Figures 1, 2).
Patient B.II.3 is a 54-year-old male, in whom CTLA-4
insufficiency was revealed by family screening at the age of 49 (2).
Fever, night sweats, and fatigue occurred just a few months later,
EBV viral load began to rise, and a generalized lymphadenopathy
was detected. In addition, pancytopenia developed in the context
of a hemophagocytic syndrome. Laboratory values showed
an IL2-receptor load of 44.141 U/ml and an EBV load of
297.000 copies/ml blood. Although a therapy with high dose
corticosteroids, rituximab, and etoposide was initiated, his
condition aggravated and he developed Aspergillus fumigatus
sepsis. Aged 51 bone marrow biopsy revealed a classical Hodgkin
lymphoma. With an adjusted chemotherapy protocol AVD
(bleomycin was excluded due to aspergillosis) the patient reached
clinical remission, subsequent bone marrow transplantation was
successfully realized and the patient is in complete remission for
more than 3 years.
Patient L.II.2 is a 20-year-old male, who initially presented
with inguinal and axillary lymphadenopathy and severe
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FIGURE 1 | Hyperinflammation, exemplified in a CTLA-4-insufficient-patient. Panel (A) shows a liver biopsy taken from patient H.II.1 at the age of 17 years with a
cholestatic giant cell hepatitis (bile marked by arrowhead, exemplary). Panels (B,C) show bone marrow trephine biopsies with nodular lymphocytic aggregates
(of T-cell origin, by IHC). In (B), subtotal replacement of hematopoiesis by fibrosis and stromal edema can be seen.
FIGURE 2 | Lymphomas in CTLA-4-insufficient-patients (A–D) showing classical Hodgkin lymphomas (mixed cellularity subtype), exemplary Reed-Sternberg cells are
highlighted by arrowhead. All cases were EBV-associated.
pancolitis, at the age of 16 years. The diagnosis of lymphocyte-
rich Hodgkin lymphoma was established based on an inguinal
lymph node biopsy.
Laboratory values remained negative for EBV, but
immunohistochemical staining was positive for CD15, CD30,
EBV-LMP, and EBV in situ-hybridization. Histological work-up
showed architectural effacement by a diffuse and partially
nodular infiltrate of lymphocytes and histiocytes; these cells were
interspersed with Reed-Sternberg cells (Figure 2).
The Hodgkin lymphoma was treated with three courses of
ABVD chemotherapy (Euronet PHL-C1 2007), the colitis
with corticosteroids, sirolimus, and belatacept and the
hypogammaglobulinemia with IGRT. PET-CT at the first
re-evaluation after 3 months showed, that the lymphoma
was now in remission. He underwent matched unrelated
bone marrow transplantation with reduced intensity 7
months after diagnosis and is now alive and well 2 years
post-BMT.
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FIGURE 3 | Gastric cancer and precursor lesions in CTLA-4-insufficient-patients. (A) Poorly differentiated EBV associated adenocarcinoma at the age of 41 years
(inlet displays chromogen in situ hybridization of EBV coded mRNA/EBER ISH). (B) Same patient at the age of 44 years with a well-differentiated EBV associated
adenocarcinoma (inlet with EBER ISH). (C) Infiltration of the lamina propria through discohesive carcinoma cells in a 25-years-old patient. (D-F) 34-years-old patient
with small poorly differentiated adenocarcinoma (D,e for macroscopy; E for histology) and larger well-differentiated adenocarcinoma (D,f for macroscopy; F for
histology). (G,H) Pyloric biopsies taken at the age of 43 years showing high grade dysplasia (G) and viral inclusions (H, highlighted by arrowhead).
FIGURE 4 | Other malignancies in CTLA-4-insufficient-patients. (A) Superficial spreading melanoma of the ear (at the age 24 years) and metastasis (B; at the age of
25 years) infiltrating striated muscle fibers. (C) Amyloid deposits (highlighted by arrowhead) were immunohistochemically positive for amyloid p in this 75-years-old
patient with multiple myeloma.
Patient JJ.II.2 is a 31-year-old male, who presented with
antibody deficiency at the age of 10 years (CVID Euroclass
B+smB-CD21low TR high). In the course of his illness,
he developed recurrent respiratory infections, intermittent
cytopenia, renal impairment necessitating dialysis, fluctuating
EBV levels, enteropathy, and bilateral granulomatous lesions in
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the lungs. At the age of 28 years a heterozygous mutation in
CTLA4 was detected.
A few months later, clinical assessment indicated a weak
patient with enlarged inguinal lymph nodes accompanied by
intermittent fevers and the diagnosis of a Hodgkin lymphoma
with mixed cellularity including bone marrow infiltration was
made; EBV-PCR detected a low positive result of 90 copies/ml
blood. Complete remission was reached by six cycles of
AVD protocol; the patient is alive and well more than 500
days after his initial cancer diagnosis without any signs of
recurrence.
Patient MM.II.1 is a 40-year-old male, who initially
presented with haemolytic anemia at the age of 14 years
and diagnostic workup led to the diagnosis of a CVID
(EUROClass B+smB-21low TR norm). Several pneumonias
and recurrent autoimmune phenomena with haemolysis and
thrombocytopenia occurred and were temporarily controlled by
corticosteroids and azathioprine.
After 13 years of clinical remission, MM.II.1 presented with
lymphadenopathy and B symptoms at the age of 33 years.
His condition deteriorated rapidly and a diagnosis of an EBV-
associated classical Hodgkin lymphoma (grade IIIB) was made
based on cervical lymph node resection (Figure 2). Laboratory
values showed an EBV load of <500 copies/ml and a CMV load
of<1,000 copies/ml blood. Complete remission was reached with
four cycles of ABVD chemotherapy protocol.
During remission, recurrent gastrointestinal irritations and
relapses of a past encephalomyelitis occurred intermittently. So
far, there are no hints for recurrence of the lymphoma and the
patient remains in remission for 7 years.
Patient K.II.1 was a 52-year-old female, who was the first out
of four patients with Non-Hodgkin-Lymphoma in our cohort.
She was diagnosed with CVID during her twenties and received
IGRT for decades. At the ages of 33 and 39 years hyper-
cellularity and lymphocytic infiltrations were found in her bone
marrow, but malignant cell growth could be ruled out. However,
6 years later at the age of 45 years, generalized lymph node
enlargement appeared accompanied with fevers, night sweats,
and weight loss. Cervical lymph node biopsy revealed clonal
lymphoproliferation with typical features of a DLBCL with EBV
association.
The lymphoma was treated with four courses of rituximab
with only partial response, thus she received four cycles of
R-CHOP 21 and could reach a complete remission.
After 4 years of remission, she developed recurrent abdominal
and retroperitoneal lymphadenopathy, but biopsies negated
malignant transformation. At the age of 51 years, her clinical
condition deteriorated soon and finally the diagnosis of a non-
EBV-associated DLBCL (grade IVb) was made based on an
additional diffuse hepatic lesion biopsy. Pathology examination
described compact atypical B cell infiltrate with a component
of high reactive T cells. The non-EBV-associated DLBCL only
responded partially to treatment with two cycles of R-CHOP, two
cycles of R-DHAP, as well as one cycle of R-BEAM. In the end,
she suffered from CMV-viremia and deceased due to pneumonia
and gastric bleeding 7 months following the relapse at the age of
52 years.
Patient UU.III.3 was a 51-year-old female, who had severe and
recurrent gastroenteritis for many years. Clinical records are rare
and even genotyping could not be made prior her death, but
family screening revealed a heterozygous CTLA4mutation in five
out of seven siblings and in four out of her five children. At the
age of 50 years she presented with inguinal lymphadenopathy
accompanied with B symptoms and she was diagnosed with
DLBCL based on inguinal lymph node resection.
Despite five cycles of R-CHOP, local radiotherapy, and radio-
immune-therapy with ibritumomab-tiuxetan, the patient died 13
months after cancer diagnosis.
Patient CO.I.1 was a 62-year-old male, whose CVID diagnosis
was first made at the age of 38 years and a heterozygous
mutation in CTLA4 was identified at the age of 61 years
following clinical assessment. His clinical history followed a
long history of recurrent but steroid-sensitive granulomatous
infiltration in kidney, skin, lung, and conjunctivae. Finally, he
complained of weight loss and fatigue over months at the age
of 62. Biopsy of a hepatic lesion revealed morphological features
of a DLBCL germline subtype. Immunohistochemical staining
showed atypical lymphoid infiltrates, which were positive for
CD20, Bcl6 and Bcl2, and negative staining for CD3, CD5, CD10,
MUM-1, TdT, and EBERish.
The lymphoma was treated with three cycles of R-CHOP
chemotherapy (two with reduced, one with full intensity), his
health deteriorated and he deceased after a short and fulminant
sepsis just 3 months after cancer onset.
Patient FF.II.1 was a 23-year-old male, who initially attracted
clinical assessment at the age of 6 years and at the age of
16 years with treatment-dependent immune thrombocytopenia
(ITP). He presented at age 22 with diffuse lymphadenopathy
and in the years prior to his diagnosis he had benign
lymphadenopathy with negative biopsies on multiple locations.
At the time of his diagnosis, the lesions had increased
in size, number, and PET-CT avidity prompting repeated
biopsies. Those revealed typical features of a Burkitt lymphoma
without EBV association. Laboratory values showed overall
lymphopenic levels and negative EBV, CMV, and toxoplasma
ranges. Immunohistochemical staining was positive for CD10,
CD20, PAX5, c-MYC, and 100% for proliferation index Ki-67.
The lesions were refractory to four cycles of R-Hyper-CVAD
and showed only a minimal response to two cycles of R-ICE.
Next, he started treatment with rituximab and selinixor on
study KPT330, but he was taken off the study because of
disease progression with worsening thoracic and retroperitoneal
lymphadenopathy. Ultimately, another therapy attempt was
started following the DA-R-EPOCH protocol, but nonetheless
the patient died of his progressive disease with thoracic and
retroperitoneal lymphadenopathy at the age of 23 years.
Gastric Cancers
Patient B.II.4 is a 47-year old female, who had manifested
with antibody deficiency, recurrent hypokalaemic periods due
to severe diarrhea, and chronic renal failure most likely due
to lymphocytic renal infiltrations during her early forties. Her
CTLA4 mutation was found at the age of 43 years by screening
of 71 unrelated patients with CVID and enteropathy (2).
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Two years prior her CTLA-4 insufficiency diagnosis, at the
age of 41 years, she developed an EBV-associated and poorly
differentiated gastric adenocarcinoma (type M, Figure 3), that
was treated by radical mucosal resection. Nonetheless the cancer
relapsed 3 years later—again EBV-associated (Figure 3)—and the
patient finally underwent total gastrectomy at the age of 44 years
and reached a complete remission; 19 lymph nodes were negative
for cancer. Her clinical condition improved steadily under
immunosuppressive therapy and today her intestinal symptoms
are well-controlled.
Patient XX.II.1 is a 44-year-oldmale, who hadmanifested with
a number of hospitalisations due to gastrointestinal symptoms
such as appendicitis and severe diarrhea, that prompted many
years on budesonide and anti-TNF-α treatment.
Gastroscopy at the age of 42 years showed severe atrophic
gastritis with extensive intestinal metaplasia, a well-known
risk-factors of gastric cancer (12). The diagnosis of an in
situ adenocarcinoma was based on two tubular adenomas
and extensive endoscopic resection of the lesions was
performed (Figure 3). Laboratory values showed EBV load
of 7,510 UI/ml blood and no CMV level, but PCR of
biopsies were positive for EBV, CMV, and in presence of
H. pylori.
He is receiving sirolimus, ustekinumab, and will start an
antibiotic treatment for H. pylori. First control by gastroscopy
6 months after diagnosis showed two quiescent tubular
adenomas with low grade dysplasia—gastrectomy might finally
be performed when aggravation occurs.
Both patients who developed EBV-associated gastric cancer
had received abatacept, a CTLA-4-Ig-fusion-protein, which is
expected to improve especially the gastrointestinal symptoms
in adult autoimmune enteropathy but could raise EBV serum
levels (13). In fact, abatacept treatment has to be interrupted
in patient B.II.4 after 7 months due to increased serum levels
of EBV copies and rituximab treatment was needed, but
nonetheless a relapse of gastric cancer developed 2 months after
interruption and patient finally underwent total gastrectomy.
However, patient B.II.4 resumed abatacept treatment 18 months
after her relapse following mucosal healing for her severe
CTLA4-associated enteropathy, reporting a repeated sustained
clinical recovery of her bowel symptoms under abatacept until
today. The second case (XX.II.1) stopped his therapy with
abatacept after 3 months when EBV level rose and switched
to sirolimus plus ustekinumab to control sustained intestinal
symptoms with protracted diarrhea. EBV load decreased within
few weeks after interruption of abatacept to <500 copies/ml
blood.
Nonetheless both patients will need yearly follow-up by
gastroscopy and carefully monitoring of EBV load.
Patient M.II.3 was a 35-year-old male, who suffered from
chronic diarrhea since he was 10 years (5). Additional features
were bacterial pneumonia and acute hepatitis with uncertain
etiology around the age of 24 years, that needed corticosteroid
pulse treatment. Around this time, he was diagnosed with CVID
and started IGRT.
Acute gastritis mucosal lesions prompted recurrent
endoscopies around the age of 28 years, and finally multiple
biopsies at the age of 34 years revealed a poorly differentiated
adenocarcinoma, a well-differentiated tubular adenocarcinoma
and epithelium cells with CMV-associated antigen; no metastasis
was found (Figure 3).
For treatment, he underwent total gastrectomy without
perioperative chemotherapy, but protracted diarrhea and
enterocolitis continued postoperatively for months despite
immunosuppressive therapy. Recurrence of cancerous lesions
has been monitored by gastroscopies, but he never fully
recovered and died 25 months after gastrectomy following a
Klebsiella pneumonia-induced sepsis.
Patient G.III.2 is a 25-year-old male, who had repeated
gastrointestinal examinations and recurrent active gastritis
over several years, which was initially diagnosed as Crohn’s
disease at the age of seven years (4). Additionally, he
developed trilineage cytopenia and CT scan examination
revealed interstitial pulmonary nodules. Despite aggressive
immunosuppressive treatment he required partial colectomy at
the age of 14 years, which improved his condition together with
budesonide and anti-TNF-α treatment. However, his atrophic
gastritis progressed and at the age of 17 years endoscopic biopsies
revealed an early invasive adenocarcinoma without EBV or
CMV association. The patient’s treatment consisted of a total
gastrectomy. Histopathology of the stomach revealed diffuse
marked chronic active gastritis with multifocal areas of low
to high grade dysplasia and an early invasive adenocarcinoma;
20 lymph nodes were negative for cancer. Remission was
reached, but enterocolitis is still active and he requires
intensive immunosuppressive therapy due to the neurological,
hematological and respiratory involvement. Nonetheless, the
patient is in complete remission for 7 years.
Patient CM.II.2 is a 29-year-old female, who has developed
recurrent infections since the age of one year and was diagnosed
with CVID at the age of 14 years, treated with IGRT.
At the age of 20 years, assessment of curious paraesthesia
and muscle power decrease revealed a vitamin B12 deficiency-
associated pernicious anemia. Following this diagnosis,
gastroscopy discovered an early gastric adenoma (gastric type)
with high grade dysplasia and without EBV or CMV association.
Endoscopic submucosal dissection wasmade and she has been on
regular follow-ups, which repetitively confirmed chronic active
gastritis. Finally, at the age of 25 years, follow-up gastroscopy
revealed a poorly differentiated gastric adenocarcinoma, again
without viral association (Figure 3).
The treatment consisted of laparoscopic subtotal gastrectomy.
Chemotherapy was not realized and the patient does not have any
cancer relapse since more than 3 years and is still treated only by
IGRT.
Other Malignancies
Patient CM.I.2 is a 75-year-old male, who has been asymptomatic
during his life regarding PID-associated symptoms. At the
age of 60 years, he presented with an axillary sarcoma and
received operative excision without chemotherapy and reached
clinical remission. Aged 75, he had developed proteinuria and
urine protein electrophoresis revealed a monoclonal peak in
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beta globulin region. Finally, bone marrow biopsy verified the
diagnosis of multiple myeloma.
Since his sister and niece (CM.II.2) have been diagnosed with
CTLA-4 insufficiency a few months prior the patient’s cancer
diagnosis, genetic testing revealed the same heterozygous variant
in CTLA4. Additional antibody test showed decreased serum
levels.
The patient recently received chemotherapy with bortezomib
and melphalan (in reduction due to renal insufficiency). Shortly
after the chemotherapy he developed complications including
pericardial and pleural effusions, he was admitted to intensive
care, but he recovered well.
To continue treatment for multiple myeloma, he was
transferred to a central hospital, where a kidney biopsy was
made, which was immunohistochemically positive for amyloid p
(Figure 4).
Patient CZ.II.2 is a 25-year-old female, who was initially
diagnosed with relapsing-remitting Multiple Sclerosis (MS)
at the age of 19 years and subsequently was noted to
be hypogammaglobulinemic at 23 years. Her neurological
symptoms were treated with several MS-targeting monoclonal
antibodies and immunosuppressive therapies over the years,
which were blamed for most of her other autoimmune features
including interstitial lung disease, lymphocytic enterocolitis, and
cytopenia, until finally a diagnosis of CTLA-4 insufficiency was
made at the age of 24 years. She showed additionally impaired
control of oncogenic viruses presenting with precancerous CIN
II and VIN II.
Her melanoma (left-ear) was first noted on routine skin
checks at the age of 24 years and was excised with clear margins
(Figure 4). Seven months later, she noted an enlarged left post-
auricular lymph node. A fine needle aspirate revealed a non-
small cell malignancy suggestive of metastatic melanoma, which
was confirmed with an excisional lymph node biopsy. PET-
CT scan revealed avid lesions scattered in her lungs and brain.
However, review of her old imaging suggested that these were
more consistent with her previously noted inflammatory lesions.
She underwent a total left neck lymph node dissection, which
revealed five involved lymph nodes out of a total of 22, with
soft tissue deposits and intramuscular extension, confirming the
diagnosis of an aggressive and unresectable stage III metastatic
melanoma. Genetic testing revealed an NRAS mutation not
amenable to BRAF immunotherapy. A follow-up PET-CT scan
revealed new lesions involving her right psoas muscle and right
axilla, with reductions in the previously noted lesions, on a
slightly higher dose of steroids (Figure 4). Biopsies of both
new lesions revealed granulomatous change, without evidence
of melanoma. Recently, the patient has commenced abatacept
therapy and remains on methotrexate and prednisolone. She is
receiving radiation therapy to her neck and surrounding area.
DISCUSSION
Primary immunodeficiencies (PIDs) are known to confer an
increased risk of cancer predisposition (14). This seems to be
explained by the impaired immune surveillance of lymphocytes
by the defective immune system. For patients with CVID an
increased susceptibility to malignancies, such as gastric cancer
and particularly lymphomas is known (15, 16). Interestingly,
this observation is paralleled by our results in CTLA-4-
insufficient patients, showing predominantly lymphoma and
gastric cancer. Lymphomas are known to occur in patients
with primary immunodeficiencies, possibly as a result of the
lymphopenia present in most patients. Gastric cancers often
arise from a chronic inflammatory tissue, which is a commonly
known risk factor (12). Despite to that, malignancies like the
multiple myeloma in older individuals should also be seen in
consideration of immune senescence.
Our findings demonstrate an elevated risk for malignancies
of 12.9% in affected CTLA4 mutation carriers. In addition,
comparing the risk of cancer between the general population
and affectedCTLA4mutations carriers, affectedCTLA4mutation
carriers had a higher cancer rate per year (Figure 5).
The median time of survival since diagnosis of cancer was
361 days, however, this appears to vary dependent on entity
(Figure 6). In 14 out of 17 patients, the diagnosis of CTLA-
4 insufficiency was made prior the diagnosis of cancer. Special
adjustment of cancer therapy because of the underlying PID was
not reported, except in patient CZ.II.2, where additional immune
dysregulatory features necessitated therapy with abatacept.
Lipopolysaccharide-responsive and beige-like anchor protein
(LRBA) deficiency seems to be a phenocopy of CTLA-4
insufficiency (17, 18). In LRBA-deficient patients, CTLA-4
is transcribed normally, but impaired membrane trafficking
induces an enhanced degradation of CTLA-4 in lysosomes (19).
However, only a single report of gastric cancer was recently
described for LRBA deficiency (20). The lack of reported
malignancies in LRBA deficiency may result of the fact that the
phenotype of LRBA deficiency is usually even more severe than
that of CTLA-4 insufficiency and patients either die at an early
age or receive HSCT, possibly prior to the development of any
malignancy.
The reported melanoma in a CTLA-4-insufficient patient
(CZ.II.2) is alerting and beyond our present understanding
of the functional interaction between immune checkpoints
and melanoma development. While the anti-CTLA-4 drug
Ipilimumab acts to upregulate antitumor immunity and shows
significant improvement in survival in metastatic melanoma,
heterozygous CTLA4 mutations should act similarly (21).
Therapy is still pending but PD-1 inhibitors are being
considered.
PD-1 blockade plus CTLA-4 insufficiency in patient CZ.II.2
should act like combined immune checkpoint inhibition, that
had shown significant benefit on survival and CTLA4-Fc could
attempt to decrease immune dysregulation (22). The possible
deterioration of metastatic lesions under CTLA4-Fc should be
considered, therefore the option of mono-chemotherapy with
alloHSCT may be the best option if the patient’s condition
permits it.
Nine out of 17 patients had steroids (5–20 mg/d), one
had additional anti-TNF-α treatment due to inflammatory
bowel disease (XX.II.1), one had additional daclizumab due
to MS (CZ.II.2), and two had received abatacept (CTLA4-Fc)
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FIGURE 5 | Incidences of selected malignancies in the averaged German and US population (reference cohort, general population, 2009–2014) and incidences in
affected CTLA4 mutation carriers (2009–2017).
FIGURE 6 | Survival rate per entity of malignancies in CTLA4 mutation carriers (n = 17), time range from day of diagnosis to last follow-up (days).
additionally in order to ameliorate the CTLA-4 insufficiency. The
occurrence of cancer in eight of 17 CTLA-4 patients without
any immunosuppression indicates that there may be an intrinsic
defect to control especially the herpes viruses, EBV, and CMV
in CTLA-4 insufficient individuals. However, further studies
and observations need to address the question whether or not
immunosuppressive therapy may have been a secondary trigger
for cancer development.
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The increased cancer risk, combined with the observation of
viral association, leads us to assume that a defective immune
surveillance of chronically virus-infected cells and the reduced
elimination of oncogenic viruses leads to deregulated cell
growth. Decreased CTLA-4 expression results in uncontrolled
proliferation of T cells with a possible overgrowth of autoreactive
clones over e.g., EBV-specific T cell clones, as known for persons
with HIV infection, but experimental data are missing (23).
As a result, monitoring of EBV and CMV replication in
blood in patients with CTLA-4 insufficiency by PCR should be
performed.
In general, EBV-infectedmemory B cells are controlledmainly
by Naturel Killer (NK) and CD8+ T cells. The quantity and
quality of the CD8+ T cell response to EBV are essential to
control the infection (24). In some PID patients an underlying
genetic disorder affecting T- and NK cell function results in
failure to control EBV infection, predisposing for EBV-associated
HLH and EBV-associated cancer (25). Recently, alerting high
frequencies of asymptomatic EBV viremia in affected and
unaffected individuals with CTLA4 mutations were described,
showing the clinical importance of further research about
CTLA-4 signaling and EBV infection (26).
Since the functional outcome of NK and CD8+ T cells
depends on a balance between activating and inhibitory signals,
costimulatory molecules such as CTLA-4 should be considered
to play a critical role in control of EBV infection. NK cells
express CTLA-4, resulting in decreased IFN-y secretion upon
engagement by the recombinant ligand CD80 (27). Notably,
CTLA4 mutation carrier NK cells show defective effector
functions, but normal peripheral maturation (28). Furthermore,
EBV-specific CD8+ T cells in EBV-associated DLBCL (CTLA4
wildtype) are functionally impaired, hence, CTLA-4 insufficiency
might push the oncogenic capacity of EBV (29).
Together, changes in the function and clonal diversity of
NK and T cells due to CTLA-4 insufficiency might be further
augmented by viral persistence and may lead to life-threatening
EBV. Whether the increased risk, however, also extends to
HPV-induced malignancies [as e.g. seen in ICOS-deficiency
(30)] needs to be monitored in affected individuals, even more
since similar precancerous lesions had been seen in patient
CZ.II.2.
Whether abatacept treatment will decrease the risk to develop
cancer in CTLA-4 insufficiency remains to be proven, as the
substitution of CTLA4-Fc ameliorates the dysregulated immune
response. Until then, HSCT should be the preferred option
and should be considered early-on in the treatment strategy of
malignancies in the context of CTLA-4 insufficiency.
Cancer predisposition in CTLA-4 insufficiency appears as
a result of immune activation with chronic inflammation,
failure to control oncogenic viruses or neoplastic cells by
immunological means, plus an intrinsic T cell impairment
due to the underlying genetic defect. These findings go along
with the observation that individuals with PIDs have intrinsic
abnormalities of the lymphoid system which result in an
increased frequency of malignant cell growth (31). Moreover,
recently published data supports this hypothesis of cancer
predisposition: Hauck et al. discussed similarly and separated
in intrinsic lymphoid abnormalities and extrinsic insufficient
cancer immunosurveillance with failure to eliminate oncogenic
viruses and chronic tissue inflammation (32). However, the
spectrum of malignancies in patients with PIDs as well as in
CTLA-4 insufficiency appears to be restricted and derived from
the same molecular defect as the immunodeficiency itself; either
in the same cell type that has been primarily affected by the
immunodeficiency or in another cell type in which malignant
transformation could occur secondarily and indirectly facilitated
by the underlying PID (32).
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